Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MOLN Molecular Partners	$3.81 -2.0%	$3.69	$3.36 ▼ $7.60	$153.99M	1.1	6,586 shs	6,597 shs
PVLA Palvella Therapeutics	$56.45 +5.0%	$34.16	$11.17 ▼ $57.19	$624.34M	-0.01	98,276 shs	118,537 shs
SAGE Sage Therapeutics	$8.68	$8.93	$4.62 ▼ $11.44	$543.54M	0.26	3.63 million shs	N/A
XNCR Xencor	$8.02 +1.5%	$8.31	$6.92 ▼ $27.24	$571.99M	0.89	764,796 shs	1.25 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MOLN Molecular Partners	-7.82%	+8.06%	-2.97%	-2.87%	-38.25%
PVLA Palvella Therapeutics	+7.24%	+10.85%	+39.20%	+125.60%	+5,375,999,900.00%
SAGE Sage Therapeutics	0.00%	0.00%	-1.36%	+33.95%	+4.83%
XNCR Xencor	-1.37%	+4.08%	-14.50%	+4.64%	-55.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MOLN Molecular Partners	2.0653 of 5 stars	3.8	2.0	0.0	2.2	0.0	0.6
PVLA Palvella Therapeutics	1.9371 of 5 stars	2.5	0.0	0.0	3.2	2.5	0.6
SAGE Sage Therapeutics	3.3661 of 5 stars	2.0	5.0	4.1	0.6	1.7	0.6
XNCR Xencor	3.6859 of 5 stars	3.4	0.0	3.9	2.6	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MOLN Molecular Partners	3.50	Strong Buy	$12.00	214.63% Upside
PVLA Palvella Therapeutics	3.09	Buy	$58.50	3.63% Upside
SAGE Sage Therapeutics	1.93	Reduce	$7.85	-9.56% Downside
XNCR Xencor	2.75	Moderate Buy	$23.71	195.69% Upside

Current Analyst Ratings Breakdown

Latest MOLN, XNCR, PVLA, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $15.00
8/19/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $66.00
8/15/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $75.00
8/15/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $60.00
8/7/2025	XNCR Xencor	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $27.00
8/7/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$31.00 ➝ $26.00
8/5/2025	PVLA Palvella Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$54.00
8/4/2025	PVLA Palvella Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$90.00
7/21/2025	PVLA Palvella Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$56.00
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MOLN Molecular Partners	$681K	226.12	N/A	N/A	$3.99 per share	0.96
PVLA Palvella Therapeutics	$42.81M	14.58	N/A	N/A	$4.32 per share	13.07
SAGE Sage Therapeutics	$41.24M	13.18	N/A	N/A	$5.89 per share	1.47
XNCR Xencor	$110.49M	5.18	N/A	N/A	$8.70 per share	0.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MOLN Molecular Partners	-$61.39M	-$2.08	N/A	N/A	N/A	N/A	-48.58%	-43.74%	10/30/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-62.30%	-43.34%	11/12/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$4.89	N/A	N/A	N/A	-427.78%	-67.10%	-58.42%	11/4/2025 (Estimated)
XNCR Xencor	-$232.62M	-$2.40	N/A	N/A	N/A	-121.52%	-25.75%	-18.19%	11/5/2025 (Estimated)

Latest MOLN, XNCR, PVLA, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2025	H1 2025	MOLN Molecular Partners	-$0.53	-$0.67	-$0.14	-$0.67	N/A	N/A
8/14/2025	Q2 2025	PVLA Palvella Therapeutics	-$0.78	-$0.86	-$0.08	-$0.86	N/A	N/A
8/6/2025	Q2 2025	XNCR Xencor	-$0.78	-$0.41	+$0.37	-$0.41	$22.59 million	$43.61 million
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	-$0.79	+$0.17	-$0.79	$16.69 million	$31.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MOLN Molecular Partners	N/A	15.28	15.28
PVLA Palvella Therapeutics	N/A	7.67	7.67
SAGE Sage Therapeutics	N/A	9.16	9.13
XNCR Xencor	N/A	5.34	5.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MOLN Molecular Partners	26.55%
PVLA Palvella Therapeutics	40.11%
SAGE Sage Therapeutics	99.22%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
MOLN Molecular Partners	5.93%
PVLA Palvella Therapeutics	20.50%
SAGE Sage Therapeutics	5.50%
XNCR Xencor	5.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
XNCR Xencor	280	71.32 million	67.59 million	Optionable

MOLN, XNCR, PVLA, and SAGE Headlines

Recent News About These Companies

Xencor to Participate at Upcoming Investor Conferences

2 hours ago | businesswire.com

Vanguard Group Inc. Trims Stake in Xencor, Inc. $XNCR

August 26 at 3:04 AM | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives $23.71 Consensus Target Price from Brokerages

August 25 at 3:07 AM | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by Analysts

August 24 at 2:42 AM | marketbeat.com

Aberdeen Group plc Grows Holdings in Xencor, Inc. $XNCR

August 23, 2025 | marketbeat.com

Royal Bank Of Canada Lowers Xencor (NASDAQ:XNCR) Price Target to $15.00

August 23, 2025 | americanbankingnews.com

Xencor, Inc. $XNCR Stock Holdings Lifted by Public Sector Pension Investment Board

August 22, 2025 | marketbeat.com

Xencor price target lowered to $15 from $32 at RBC Capital

August 21, 2025 | msn.com

Q3 Earnings Estimate for Xencor Issued By Leerink Partnrs

August 11, 2025 | marketbeat.com

Wedbush Estimates Xencor's Q3 Earnings (NASDAQ:XNCR)

August 11, 2025 | marketbeat.com

William Blair Analysts Boost Earnings Estimates for Xencor

August 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.37 EPS

August 10, 2025 | marketbeat.com

Xencor (XNCR) Receives a Buy from Leerink Partners

August 9, 2025 | theglobeandmail.com

Xencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

August 9, 2025 | finance.yahoo.com

Xencor (XNCR) Q2 Revenue Jumps 82%

August 9, 2025 | theglobeandmail.com

Xencor (NASDAQ:XNCR) Hits New 12-Month Low on Analyst Downgrade

August 8, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Given New $27.00 Price Target at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Wedbush Lowers Xencor (NASDAQ:XNCR) Price Target to $26.00

August 8, 2025 | marketbeat.com

Xencor price target lowered to $26 from $31 at Wedbush

August 8, 2025 | finance.yahoo.com

Primecap Management Co. CA Has $103.86 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

August 8, 2025 | marketbeat.com

XTX Topco Ltd Acquires 35,627 Shares of Xencor, Inc. (NASDAQ:XNCR)

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, XNCR, PVLA, and SAGE Company Descriptions

Molecular Partners NASDAQ:MOLN

$3.81 -0.08 (-1.95%)

Closing price 03:58 PM Eastern

Extended Trading

$3.82 +0.00 (+0.03%)

As of 05:56 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Palvella Therapeutics NASDAQ:PVLA

$56.45 +2.69 (+5.00%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Sage Therapeutics NASDAQ:SAGE

$8.68 0.00 (0.00%)

As of 07/31/2025

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Xencor NASDAQ:XNCR

$8.02 +0.12 (+1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$8.02 +0.01 (+0.06%)

As of 04:10 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time